Cresset Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Cresset Asset Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-84,930	Closed	-$1.21M	–	2176
2024 Q3	$1.21M	Sell	84,930 -430	-0.5%	-$6.1K	﹤0.01%	1068
2024 Q2	$1.12M	Buy	85,360 +8,447	+11%	+$112K	﹤0.01%	1008
2024 Q1	$1.07M	Buy	76,913 +19,824	+35%	+$288K	0.01%	943
2023 Q4	$815K	Sell	57,089 -16,783	-23%	-$238K	﹤0.01%	984
2023 Q3	$1.14M	Buy	73,872 +15,932	+27%	+$247K	﹤0.01%	790
2023 Q2	$921K	Buy	+57,940	New	+$949K	﹤0.01%	984
2021 Q4	–	Sell	-13,983	Closed	-$229K	–	1290
2021 Q3	$229K	Buy	+13,983	New	+$235K	﹤0.01%	970
2019 Q2	–	Sell	-1,600	Closed	-$33K	–	1548
2019 Q1	$33K	Buy	+1,600	New	+$32.2K	﹤0.01%	901

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cresset Asset Management's TAK Position: Q4 2024 in Review

Cresset Asset Management sold out of Takeda Pharmaceutical (TAK) in Q4 2024, closing a stake of 84,930 shares — an estimated $1.21M sold.

Cresset Asset Management first reported a position in TAK in Q1 2019 and held it in 8 quarters. The position peaked at $1.21M in Q3 2024. 299 funds tracked by Wall St. Rank hold TAK as of Q4 2024.

Cresset Asset Management reported no remaining Takeda Pharmaceutical position as of Q4 2024 after selling out during the quarter.
Cresset Asset Management sold 84,930 Takeda Pharmaceutical shares in Q4 2024, an estimated $1.21M.
Cresset Asset Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 8 quarters.
Cresset Asset Management's Takeda Pharmaceutical position peaked at $1.21M in Q3 2024.
299 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.